Elevated TAB182 enhances the radioresistance of esophageal squamous cell carcinoma through G2 ‐M checkpoint modulation

ConclusionTAB182 potentiates the radioresistance of ESCC cells by modulating the G2 ‐M checkpoint through its interaction with FHL2. Thus, TAB182 may become an ideal biomarker and therapeutic target of ESCC radiotherapy.

Source: Cancer Medicine - March 31, 2021 Category: Cancer & Oncology Authors: Yuandong Cao, Aidi Gao, Xiaoqing Li, Han Min, Chao He, Xinchen Sun, Wei ‐Qun Ding, Jundong Zhou Tags: ORIGINAL RESEARCH Source Type: research